|
| RESEARCH PAPER |
|
|
|
| Year : 2006 | Volume
: 38
| Issue : 5 | Page : 341-345 |
| |
Effect of eugenol on animal models of nociception
R Kurian1, DK Arulmozhi2, A Veeranjaneyulu1, SL Bodhankar1
1 Department of Pharmacology, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune 411 038, India
2 Discovery Biology, Advinus Therapeutics, Bioresearch Centre, Pune 411057, Maharashtra, India
| Date of Submission | 31-Mar-2006 |
| Date of Decision | 28-Jun-2006 |
| Date of Acceptance | 03-Jul-2006 |
Correspondence Address:
S L Bodhankar
Department of Pharmacology, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune 411 038
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.27702
Objective: To investigate the antinociceptive potential of eugenol on different pain models in mice.
Materials and Methods : Eugenol was evaluated (1-100 mg/kg, i.p.) in various experimentally induced pain models like, formalin induced hyperalgesia, acetic acid induced abdominal constrictions, and thermal pain experiment using Eddy's hot plate.
Results : Eugenol significantly inhibited acetic acid induced abdominal constrictions, with the maximal effect (92.73% inhibition) at 100 mg/kg. In formalin induced paw licking pain model, eugenol exhibited more pronounced antinociceptive effect in the inflammatory phase than the neurogenic phase (maximal effect was 70.33% and 42.22%, respectively, at 100 mg/kg, i.p). A mild reduction in the pain response latency at 100 mg/kg, i.p. dose of eugenol was observed in the hotplate thermal pain studies in mice. In the rotarod motor coordination experiment eugenol reduced the endurance time at the dose of 100 mg/kg, i.p.
Conclusion: The data suggest that eugenol exerts antinociceptive activity in different experimental models of pain in mice.
Keywords: Antinociceptive, clove oil, pain models.
How to cite this article:
Kurian R, Arulmozhi D K, Veeranjaneyulu A, Bodhankar S L. Effect of eugenol on animal models of nociception. Indian J Pharmacol 2006;38:341-5 |
| Introduction | |  |
Eugenol (4-allyl-2-methoxyphenol), the principal chemical constituent of clove oil has been primarily derived from a variety of plant sources, including Eugenia caryophyllus and Myristica fragrans . For years eugenol has been used in dental practice to relieve pain arising from a variety of sources, including pulpitis and dentinal hypersensitivity. In the recent past, a wealth of literature has been generated on eugenol's antidepressant, antistress, anticonvulsant, and analgesic activities.[1],[2],[3] Eugenol is also reported to possess antiinflammatory, antioxidant, anaesthetic and muscle relaxant properties.[4],[5],[6]
The objective of the present investigation was to study a range of doses of eugenol (from 1 to 100 mg/kg) towards possible analgesic potential in both peripheral and central experimental pain models.
| Materials and Methods | | |
Chemicals
Eugenol and indomethacin were purchased from Sigma Chemical Co. (St. Louis, USA). Pentazocine lactate (Fortwinβ Ranbaxy, India) and diazepam (Calmposeβ Ranbaxy, India) were obtained as injections from local market. Eugenol and indomethacin were dissolved in 0.5% Tween 80 in saline. Pentazocine and diazepam were diluted with saline.
Animals
Adult male Swiss albino mice (22-26 g) were obtained from the National Toxicology Centre, Pune, India. The animals were randomly allocated to treatment groups (six animals per group, per treatment) in polypropylene cages with paddy husk as bedding. Animals were housed at a temperature of 24±2oC and relative humidity of 30 to 70%. A 12:12 light:dark cycle was followed. All animals had free access to water and standard pelleted laboratory animal diet. All the experimental protocols were approved by the Institutional Animal Care and Use Committee of Poona College of Pharmacy, Pune, India and were in accordance with the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Forests and Environment, Government of India. Rules of the CPCSEA are based on ILAR (Institute of Laboratory Animal Resources, USA) guidelines.
Acetic acid induced abdominal constrictions in mice
The i.p. injection of acetic acid (1%), resulted in constriction of abdominal muscle together with a stretching of hind limbs. This procedure was carried out as described by Santos et al .[7] Eugenol (1-100 mg/kg) and positive control indomethacin (20 mg/kg) were administered i.p., 15 min prior to acetic acid injection. The number of writhing movements was counted for 30 min, from the time immediately after acetic acid injection. Antinociception was expressed as the number of abdominal constrictions between saline treated control and animals pretreated with eugenol or indomethacin.
Formalin induced paw licking in mice
This procedure was essentially similar to that described by Hunskaar and Hole.[8] Mice were injected intraperitoneally with eugenol (1-100 mg/kg) or 0.5% Tween 80 (10 ml/kg) or indomethacin (20 mg/kg). Fifteen minutes later 20 µl of 1% formalin was injected subcutaneously under the dorsal surface of the hind paw, and the animals were observed in the chambers. The time spent for licking the paw injected with formalin was counted for 30 min post formalin injection and considered as indicative of pain stimuli. The formalin test had two distinctive phases, possibly reflecting different types of pain. The first phase of the nociceptive response normally peaked at 5 min and the second phase 20 to 30 min after formalin injection. This represented neurogenic and inflammatory responses, respectively.
Hot plate test in mice
The hot plate test was carried out according to the method described by Eddy and Leimbach.[9] Animals were placed on the hot plate (Ugo Basile, Italy) maintained at 55±1oC and the time between placement on the hot plate and the occurrence of either licking of the paws, shaking, or jumping off from the plate was recorded as response latency. Mice with basal latency of more than 10 sec were not included in the study. The response latencies was measured before distraction (basal) and after drug treatment [eugenol (1-100 mg/kg, i.p.) or 0.5% Tween 80 (10 ml/kg, i.p.) or pentazocine (10 mg/kg, i.p.)] at 30, 60, 90, 120 and 180 min. The cut off time for hot plate latency was set at 20 sec.
Motor coordination (rotarod test) in mice
A rotarod tread mill device (Techno, India) was used for the evaluation of motor coordination. Mice were placed on a horizontal rotating (16 RPM) rod. These mice had been selected for their ability to remain on the revolving bar for a 2 min period. Fifteen minutes after the administration of either eugenol (30 and 100 mg/kg, i.p.) or diazepam (5 mg/kg, i.p.), each mouse was placed on the rotating rod for 60 sec, at intervals of 30 min for 3 h.[10] The endurance time for each mouse on the rota-rod was noted.
Statistical analysis
Values are expressed as mean±SEM. The statistical significance of difference between the means was analysed by one-way non-parametric ANOVA and Dunnett's test. P <0.05 was considered significant. All the statistical manipulations were carried out using GraphPad® Prism Software (Graphpad Software Inc., USA).
| Results | | |
Acetic acid induced abdominal constrictions in mice
The results of the abdominal constriction test are shown in [Figure - 1]. Eugenol elicited a dose-dependent inhibition of abdominal constrictions compared with the control group. Eugenol produced 10.61% inhibition at 1 mg/kg dose, with a maximal of inhibition 92.73% ( P <0.001; F=8.20) at 100 mg/kg, which was comparable to indomethacin (93.64% inhibition at 20 mg/kg, i.p.).
Formalin induced paw licking in mice
Eugenol exhibited no effect during the neurogenic phase (0-10 min) of formalin induced licking in mice at 1 mg/kg, 11.67% inhibition at 10 mg/kg, i.p., and 42.22% at 100 mg/kg ( P <0.001; F=5.30) compared with the vehicle treated animals. The standard, indomethacin (20 mg/kg) caused 63.93% inhibition. [Figure - 2]
A mild inhibitory effect (3.14%) with eugenol on the inflammatory phase (20 to 30 min) of the formalin induced paw licking in mice was observed at 1 mg/kg, and a statistically significant maximal inhibition (70.33% inhibition) was observed at 100 mg/kg ( P <0.05; F=5.69). The standard drug, indomethacin (20 mg/kg), also exhibited a statistically significant inhibition (66.18%) of the inflammatory phase. [Figure - 3]
Hot plate test in mice
Eugenol (1 to 100 mg/kg) pretreatment increased the response latency in the hot plate test. This, however, was not statistically significant. The centrally acting analgesic pentazocine also increased the response latencies at various time points.
Motor coordination in mice
Eugenol administered intraperitoneally at 30 mg/kg did not affect motor coordination. A dose of 100 mg/kg, however, produced a statistically insignificant reduction in the endurance time at 60 minutes. The standard drug, diazepam at 5 mg/kg, i.p. dose exhibited a statistically significant ( P <0.05) effect on motor coordination by reducing the endurance time at the various times points. [Figure - 4]
| Discussion | | |
In the present investigation, eugenol was studied for its nociceptive activity in both peripheral and central algesic models. This study differs from the earlier reports on the analgesic activity of eugenol[11],[12] primarily with respect to the route of administration, the doses employed, and the source of eugenol.
The intensity of analgesic effect of eugenol at 100 mg/kg dose was similar to that of indomethacin (20 mg/kg, i.p.) in acetic acid induced abdominal constrictions in mice. Acetic acid causes inflammatory pain by inducing capillary permeability[13] and liberating endogenous substances that excite pain nerve endings.[14] NSAIDs can inhibit COX in peripheral tissues and, therefore, interfere with the mechanism of transduction of primary afferent nociceptors.[15] The mechanism of analgesic effect of eugenol could probably be due to blockade of the effect or the release of endogenous substances that excite pain nerve endings similar to that of indomethacin and other NSAIDs. Recently, eugenol and its derivatives have been reported to exert inhibitory effect on various mediators of inflammation. This includes inhibition of lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages.[16],[17]
Eugenol exhibited an efficacy comparable to that of indomethacin in inhibiting neurogenic (first phase) and inflammatory (second phase) pain stimuli caused by formalin. The formalin test is used to evaluate the mechanism by which an animal responds to moderate, continuous pain generated by the injured tissue.[18] This test is characterised by two phases. The early phase (immediately after injection) seems to be caused by C-fibre activation due to the peripheral stimulus. The late phase (starting approximately 20 min after formalin injection) appears to depend on the combination of an inflammatory reaction, activation of NMDA and non-NMDA receptors, and the NO cascade[19] in the peripheral tissue and functional changes in the dorsal horn of the spinal cord.[18] Both these functional changes appear to be initiated by the C-fibre barrage during the early phase and to be related to excitatory amino acid (EAA) release in the spinal cord and activation of NMDA receptor subtypes. The formalin test has been used to evaluate the antinociceptive effects of competitive and non-competitive NMDA receptor antagonists administered intrathecally and systemically.[20] CGP 37849, memantine, ketamine and dextromethorphan were reported to have antinociceptive activity in formalin test[21]
Although a wealth of literature is available on the inhibitory effect of eugenol on prostaglandin bio-synthesis and or nerve conduction as shown in the rat vagus nerve,[22] there has been a recent upsurge in the research focus on the role of vanilloid receptors and calcium channels in the antinociceptive action of eugenol.
In a comparative study of b-caryophyllene oxide, eugenol, and nifedipine it was reported that eugenol blocked calcium channels. This was demonstrated in voltage clamp experiments in cardiac myocytes.[23] In cell lines stably expressing human N-type calcium channels, eugenol reportedly inhibited high-voltage-activated calcium currents.[24]
The role of vanilloid receptor in the antinociceptive activity of eugenol becomes evident from the studies conducted by Yang et al .[25] In vanilloid receptor 1 (TRPV1 or VR1), expressing human embryonic kidney (HEK) 293 cells and trigeminal ganglion neurons, eugenol activated inward currents while capsazepine, a competitive vanilloid receptor antagonist, completely blocked eugenol induced inward currents. This experiment supports the in vivo studies carried out by Ohkubo and Shibata [26] who demonstrated the inhibitory effect of capsazepine on eugenol induced antinociceptive activity in mice. These studies provide strong evidence that eugenol produces its antinociceptive effects through different mediators and, at least in part, via blockade of calcium channels and vanilloid receptor modulation.
Eugenol produced antinociception against thermal induced pain stimuli in mice at various time points post treatment. The effect observed was, however, very mild and not statistically significant. The hot plate test is considered to be selective for opioid-like compounds, which are centrally acting analgesics in several animal species.[27] In motor coordination test using rotarod apparatus, eugenol at 100 mg/kg, i.p. exhibited an insignificant sedative effect that was evidenced by reduction in endurance time. This could be the possible explanation for its mild central analgesic activity observed in hot plate test.
| Conclusion | | |
Eugenol administered intraperitoneally exhibits antinociceptive activity and possibly exerts its effect through diverse mechanisms that may involve both central and peripheral pathways. Present data support the traditional application of eugenol as a dental analgesic. Further pharmacodynamic investigations are required to understand the precise mechanism of antinociception exhibited by eugenol.
| Acknowledgments | | |
We thank Dr. S.S. Kadam and Dr. K.R. Mahadik (Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune) for their constant encouragement in the work.
| References | | |
| 1. | Prakash P, Gupta N. Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. Indian J Physiol Pharmacol 2005;49:725-31.  [PUBMED] |
| 2. | Irie Y, Itokazu N, Anjiki N, Ishige A, Watanabe K, Keung WM. Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein-III in the hippocampus. Brain Res 2004;1011:243-6. [PUBMED] [FULLTEXT] |
| 3. | Dallmeier Zelger KR, Zelger JL, Carlini EA. New anticonvulsants derived from 4-allyl-2-methoxyphenol (Eugenol): Comparison with common antiepileptics in mice. Pharmacology 1983;27:40-9. [PUBMED] |
| 4. | Sell AB, Carlini EA. Anesthetic action of methyleugenol and other eugenol derivatives. Pharmacology 1976;14:367-77. [PUBMED] |
| 5. | Ko FN, Liao CH, Kuo YH, Lin YL. Antioxidant properties of demethyldiisoeugenol. Biochim Biophys Acta 1995;1258:145-52. [PUBMED] |
| 6. | Dohi T, Anamura S, Shirakawa M, Okamoto H, Tsujimoto A. Inhibition of lipoxygenase by phenolic dental medicaments. Jpn J Pharmacol 1991;55:547-50. [PUBMED] [FULLTEXT] |
| 7. | Santos ARS, Filhe VC, Niero R, Viana AM, Moreno FN, Campos MM, et al. Analgesic effects of callus culture from selected species of Phyllanthus. J Phar Pharmacol 1994;46:755-9. |
| 8. | Hunskaar S, Hole K. The formalin test in mice: Dissociation between inflammatory and non-inflammatory pain. Pain 1987;30:103-14. [PUBMED] [FULLTEXT] |
| 9. | Eddy NB, Leimbach D. Synthetic analgesics: II. Dithienylbutenyl and dithienylbutylamines. J Pharmacol Exp Ther 1953;107:385-93. [PUBMED] |
| 10. | Perez, GRM, Perez LJA, Garcia DLM, Sossa MH. Neuropharmacological activity of S olanum nigrum fruit. J Ethnopharmacol 1998;62:43-8. |
| 11. | Ahmed M, Amin S, Islam M, Takahashi M, Okuyama E, Hossain CF. Analgesic principle from Abutilon indicum . Pharmazie 2000;55:314-6. |
| 12. | Ohkubo T, Shibata M. The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol. J Dent Res 1997;76: 848-51. |
| 13. | Amico-Roxas M, Caruso A, Trombadore S, Scifo R, Scapagini U. Gangliosides antinociceptive effects in rodents. Arch Int Pharmacodyn Ther 1984;272: 103-117. |
| 14. | Raj PP. Pain mechanism. In: Raj PP, editor. Pain medicine: A comprehensive review. 1st ed. Missouri :Mosby-Year Book; 1996. p.12-23. |
| 15. | Fields HL. Analgesic drugs. In: Day W, editor. Pain. 1st ed. USA: Mac-Graw-Hill; 1987. p. 272. |
| 16. | Kim SS, Oh OJ, Min HY, Park EJ, Kim Y, Park HJ et al . Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Life Sci 2003;73:337-48. |
| 17. | Murakami Y, Shoji M, Hirata A, Tanaka S, Yokoe I, Fujisawa S. Dehydroisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch Biochem Biophys 2005;434:326-32. [PUBMED] [FULLTEXT] |
| 18. | Abbot FV, Franklin KB, Westbrook RF. The formalin test scoring properties of the first and second phase of the pain response in rats. Pain 1995;60:91-102. |
| 19. | Davidson EM, Carlton SM. Intraplantar injection of dextrophan, ketamine or memantine attenuates formalin induced behaviors. Brain Res 1998;785: 136-42. [PUBMED] [FULLTEXT] |
| 20. | Eisenberg E, Vos BP, Strassman AM. The NMDA antagonist memantine blocks pain behavior in a rat model of formalin induced facial pain. Pain 1993;54: 301-7. [PUBMED] [FULLTEXT] |
| 21. | Berrino L, Oliva P, Massimo F, Aurilio C, Maione S, Grella A. Antinociceptive effect in mice, of intraperitoneal N-methyl-D-aspartate receptor antagonists in the formalin test. Eur J Pain 2003;7:131-57. |
| 22. | Brodin P. Differential inhibition of A, B, and C fibres in the rat vagus nerve by lidocanine, eugenol and formaldehyde. Arch Oral Biol 1985;30:477-80. [PUBMED] |
| 23. | Sensch O, Vierling W, Brandt W, Reiter M. Effects of inhibition of calcium and potassium currents in guinea-pig cardiac contraction: comparision of β -caryophyllene oxide, eugenol and nifedipine. Br J Pharmacol 2000;131: 1089-96. [PUBMED] [FULLTEXT] |
| 24. | Lee MH, Yeon KY, Park CK, Li HY, Fang Z, Kim MS, et al . Eugenol inhibits calcium currents in dental afferent neurons. J Dent Res 2005;84:848-51. |
| 25. | Yang BH, Piao ZG, Kim YB, Lee CH, Park K, Kim JS, et al . Activation of vanilloid receptor (VR1) by eugenol. J Dent Res 2003;82:781-85. |
| 26. | Ohkubo T, Shibata M. The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol. J Dent Res 1997;76: 848-51. |
| 27. | Janssen PAJ, Niememegeers CJ, Dony GH. The inhibitory effects of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawal reflex in rats. Arzneimittelforschung 1963;13:502-7. |
Figures
[Figure - 1], [Figure - 2], [Figure - 3], [Figure - 4]
| This article has been cited by | | 1 |
Effects of intramuscularly injected plant-derived antimicrobials in the mouse model |
|
| Elizabeth J. Johnson, Jingyue Ellie Duan, Kanokwan Srirattana, Kumar Venkitanarayanan, Edan R. Tulman, Xiuchun Cindy Tian | | Scientific Reports. 2022; 12(1) | | [Pubmed] | [DOI] | | | 2 |
Anti-inflammatory and anti-nociceptive effects of Cinnamon and Clove essential oils nanogels: an in vivo study |
|
| Fariba Esmaeili, Masoumeh Zahmatkeshan, Yaser Yousefpoor, Hiva Alipanah, Ehsan Safari, Mahmoud Osanloo | | BMC Complementary Medicine and Therapies. 2022; 22(1) | | [Pubmed] | [DOI] | | | 3 |
Evaluation of the antinociceptive effects of a selection of triazine derivatives in mice |
|
| Valiollah Hajhashemi, Ghadamali Khodarahmi, Parvin Asadi, Hamed Rajabi | | The Korean Journal of Pain. 2022; 35(4): 440 | | [Pubmed] | [DOI] | | | 4 |
Pulegone and Eugenol Oral Supplementation in Laboratory Animals: Results from Acute and Chronic Studies |
|
| Carla M. Ribeiro-Silva, Ana I. Faustino-Rocha, Rui M. Gil da Costa, Rui Medeiros, Maria J. Pires, Isabel Gaivão, Adelina Gama, Maria J. Neuparth, Joana V. Barbosa, Francisco Peixoto, Fernão D. Magalhães, Margarida M. S. M. Bastos, Paula A. Oliveira | | Biomedicines. 2022; 10(10): 2595 | | [Pubmed] | [DOI] | | | 5 |
Pharmacological Properties and Health Benefits of Eugenol: A Comprehensive Review |
|
| Muhammad Farrukh Nisar, Mahnoor Khadim, Muhammad Rafiq, Jinyin Chen, Yali Yang, Chunpeng Craig Wan, Antonella Smeriglio | | Oxidative Medicine and Cellular Longevity. 2021; 2021: 1 | | [Pubmed] | [DOI] | | | 6 |
Eugenol, a Promising Building Block for Biobased Polymers with Cutting-Edge Properties |
|
| Roberto Morales-Cerrada, Samantha Molina-Gutierrez, Patrick Lacroix-Desmazes, Sylvain Caillol | | Biomacromolecules. 2021; 22(9): 3625 | | [Pubmed] | [DOI] | | | 7 |
The effects of eugenol nanoemulsion on pain caused by arteriovenous fistula cannulation in hemodialysis patients: A randomized double-blinded controlled cross-over trial |
|
| Maryam Maghbool, Tomaj Khosravi, Salman Vojdani, Mahsa Rostami Chaijan, Fariba Esmaeili, Amir Amani, Fatemeh Rezayat, Ramin Nasimi Doost Azgomi, Shadan S. Mehraban, Mohammad Hashem Hashempur | | Complementary Therapies in Medicine. 2020; 52: 102440 | | [Pubmed] | [DOI] | | | 8 |
Synergistic interaction between 4-allyl-1-hydroxy-2-methoxybenzene (
eugenol
) and diclofenac: An isobolograpic analysis in Wistar rats
|
|
| Olga Edith González-Lugo, Amaury Pozos-Guillén, Patricia Ponce-Peña, Ismael Lares-Asseff, Diana María Escobar-García, Isaac Campos-Cantón, Angel Antonio Vértiz-Hernández | | Drug Development Research. 2020; 81(8): 978 | | [Pubmed] | [DOI] | | | 9 |
Evaluation of the Antinociceptive Activity ofOcimum gratissimumL. (Lamiaceae) Essential Oil and its isolated Active Principles in Mice |
|
| L. I. G. Paula-Freire,M. L. Andersen,G. R. Molska,D. O. Köhn,E. L. A. Carlini | | Phytotherapy Research. 2013; 27(8): 1220 | | [Pubmed] | [DOI] | | | 10 |
Validated RP-HPLC method to estimate eugenol from commercial formulations like Caturjata Churna, Lavangadi Vati, Jatiphaladi Churna, Sitopaladi Churna and clove oil |
|
| Sagar Saran,Sasikumar Menon,Sunita Shailajan,Priyanka Pokharna | | Journal of Pharmacy Research. 2013; 6(1): 53 | | [Pubmed] | [DOI] | | | 11 |
Effects of different extracts of Eugenia caryophyllata on pentylenetetrazole-induced seizures in mice |
|
| Mahmoud Hosseini | | Journal of Chinese Integrative Medicine. 2012; 10(12): 1476 | | [Pubmed] | [DOI] | | | 12 |
Acute effect of essential oil of Eugenia caryophyllata on cognition and pain in mice |
|
| Sumita Halder, Ashish K. Mehta, Pramod K. Mediratta, Krishna K. Sharma | | Naunyn-Schmiedeberg s Archives of Pharmacology. 2012; | | [VIEW] | [DOI] | | | 13 |
Analgesic-like activity of essential oils constituents |
|
| De Sousa, D.P. | | Molecules. 2011; 16(3): 2233-2252 | | [Pubmed] | | | 14 |
Eugenol: A natural compound with versatile pharmacological actions |
|
| Pramod, K., Ansari, S.H., Ali, J. | | Natural Product Communications. 2010; 5(12): 1999-2006 | | [Pubmed] | | | 15 |
Design and synthesis of substituted pyrrole derivatives as COX-2 inhibitors |
|
| Kumar, R., Subramanian, A., Masand, N., Patil, V.M. | | Digest Journal of Nanomaterials and Biostructures. 2010; 5(3): 667-674 | | [Pubmed] | | | 16 |
Evaluation of analgesic activity of Casuarina equisetifolia frost (Casuarinaceae) |
|
| Aher, A.N., Pal, S.C., Yadav, S.K., Patil, U.K., Bhattacharya, S. | | Asian Journal of Chemistry. 2010; 22(5): 3525-3230 | | [Pubmed] | | | 17 |
Screening of alcoholic extract of Eupatorium triplinerve Vahl and its fractions for its antinociceptive activity |
|
| Cheriyan, B.V., Venkatadri, Viswanathan, Kamalakannan | | Indian Drugs. 2009; 46(10): 55-60 | | [Pubmed] | | | 18 |
The nociceptive and anti-nociceptive effects of white mineral trioxide aggregate |
|
| Abbasipour, F., Rastqar, A., Bakhtiar, H., Khalilkhani, H., Aeinehchi, M., Janahmadi, M. | | International Endodontic Journal. 2009; 42(9): 794-801 | | [Pubmed] | | | 19 |
Anti-inflammatory and antinociceptive activities of eugenol essential oil in experimental animal models |
|
| Daniel, A.N., Sartoretto, S.M., Schmidt, G., Caparroz-Assef, S.M., Bersani-Amado, C.A., Cuman, R.K.N. | | Brazilian Journal of Pharmacognosy. 2009; 19(1 B): 212-217 | | [Pubmed] | | | 20 |
The nociceptive and anti-nociceptive effects of white mineral trioxide aggregate |
|
| F. Abbasipour,A. Rastqar,H. Bakhtiar,H. Khalilkhani,M. Aeinehchi,M. Janahmadi | | International Endodontic Journal. 2009; 42(9): 794 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
